This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zwelling, L. A. Articles by Farquhar, D. Search for Related Content PubMed PubMed Citation Articles by Zwelling, L. A. Articles by Farquhar, D.

N-(5,5-Diacetoxypentyl)doxorubicin: A Novel Anthracycline Producing DNA Interstrand Cross-Linking and Rapid Endonucleolytic Cleavage in Human Leukemia Cells¹

Department of Medical Oncology, Division of Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

The cytotoxic and DNA-damaging effects of a novel alkylating anthracycline, N-(5,5-diacetoxypentyl)doxorubicin, were quantified in HL-60 human leukemia cells and in an intercalator-resistant daughter line, HL-60/AMSA. The new drug was cytotoxic to both lines at doses as low as 50 nM for 1 h. N-(5,5-Diacetoxypentyl)doxorubicin produced DNA interstrand cross-linking in both lines. The cross-linking appeared to increase in both lines following drug treatment, but the increase was greater in the resistant line. This appeared to be due to an underestimation of cross-linking, particularly in sensitive HL-60, secondary to time-dependent DNA fragmentation that followed drug removal. This time-dependent DNA fragmentation was probably endonucleolytic cleavage (a feature of apoptosis) as characteristic nucleosomal ladders were produced by N-(5,5-diacetoxypentyl)doxorubicin treatment in a cotemporal time-dependent fashion. This novel anthracycline is the first of a family of alkylating anthracyclines designed to be water soluble, easy to formulate, and capable of producing DNA interstrand cross-linking. Because this last characteristic has previously been associated with doxorubicin analogues of great potency and low toxicity, these newer, more readily formulated drugs may have great clinical utility.

¹ This study was supported by USPHS Research Grant CA40090 (L. A. Z.), American Cancer Society Grant CH-324D (L. A. Z.), a grant from the Physicians Referral Service of the M. D. Anderson Cancer Center (L. A. Z.), and a grant from the University of Texas, M. D. Anderson Cancer Foundation (D. F.).

² To whom correspondence should be addressed, at Box 52, 1515 Holcombe Blvd., Houston, TX 77030.

Received 8/30/91. Accepted 10/29/91.

This article has been cited by other articles:

				P. A. McCarron, S. A. Olwill, W. M.Y. Marouf, R. J. Buick, B. Walker, and C. J. Scott Antibody Conjugates and Therapeutic Strategies Mol. Interv., December 1, 2005; 5(6): 368 - 380. [Abstract] [Full Text] [PDF]